71 results about "Myonectin" patented technology

Laminin and specific laminin-derived protein fragments are disclosed as potent inhibitors of Alzheimer's disease type amyloidoses. A specific region is identified within laminin which interacts with the Alzheimer's disease beta-amyloid protein and contributes to the observed inhibitory and therapeutic effects. A prominent ~130 kilodalton band in laminin was found in human serum and cerebrospinal fluid which primarily interacted with Abeta as determined by ligand blotting methodology. This ~130 kilodalton laminin fragment is known as the E8 fragment and is also believed to consist of the globular domains of the laminin A chain. The interaction of specific laminin fragments such as the newly discovered ~130 kDa protein is believed to bind Abeta in biological fluids and keep it in a soluble state.

Described herein are anti-MCAM antibodies and antigen binding fragments thereof that are capable of inhibiting the interaction between MCAM and its ligand, a protein comprising a laminin α-4 chain. These anti-MCAM antibodies and antigen binding fragments thereof may be useful for, for example, treating inflammatory conditions characterized by the infiltration of MCAM-expressing cells into a site of inflammation in the body.

The present disclosure related to isolated laminin-521, methods for making recombinant laminin-521, host cells that express recombinant laminin-521, and compositions containing laminin-521. Laminin-521 can maintain stem cells in vitro pluripotency, enable self-renewal, and enable single cell survival of human embryonic stem cells. When pluripotent human embryonic stem cells are cultured on plates coated with a matrix of recombinant laminin-521 (laminin 11), in the absence of differentiation inhibitors or feeder cells, the embryonic stem cells proliferate and maintain their pluripotency. It has also been discovered that human recombinant laminin-521 (laminin-11) provides single cell survival of stem cells after complete dissociation into a single cell suspension. Useful cell culture mediums containing at most 3.9 ng / ml of beta fibroblast growth factor (bFGF) are also described herein.

Gene expression profiling and hierarchial clustering analysis readily distinguish normal ovarian epithelial cells from primary ovarian serous papillary carcinomas. Laminin, tumor-associated calcium signal transducer 1 and 2 (TROP-1 / Ep-CAM; TROP-2), claudin 3, claudin 4, ladinin 1, S100A2, SERPIN2 (PAI-2), CD24, lipocalin 2, osteopontin, kallikrein 6 (protease M), kallikrein 10, matriptase and stratifin were found among the most highly overexpressed genes in ovarian serous papillary carcinomas, whereas transforming growth factor beta receptor III, platelet-derived growth factor receptor alpha, SEMACAP3, ras homolog gene family, member I (ARHI), thrombospondin 2 and disabled-2 / differentially expressed in ovarian carcinoma 2 (Dab2 / DOC2) were significantly down-regulated. Therapeutic strategy targeting TROP-1 / Ep-CAM by monoclonal chimeric / humanized antibodies may be beneficial in patients harboring chemotherapy-resistant ovarian serous papillary carcinomas.

Glossy ganoderma as a traditional Chinese medicine is called immortal grass since ancient times and known as the ability to treat various diseases; a pair of lingzhiol A optical enantiomers is purified from ganoderma lucidum, and the lingzhiol A optical enantiomers have obvious effects on inhibiting rat renal mesangial cell strains induced by high glucose to generate reactive oxide species, IL-6, fibronectin and IV type collagen, and also can obviously inhibit the phosphorylation of the renal tubular epithelial cell Smad3 induced by TGF-beta1, so that the application prospect of the compound in preparation of medicines for treating diabetic nephropathy and chronic nephropathy is shown.

Disclosed herein are point mutations in the LMNA gene that cause HGPS. These mutations activate a cryptic splice site within the LMNA gene, which leads to deletion of part of exon 11 and generation of a mutant Lamin A protein product that is 50 amino acids shorter than the normal protein. In addition to the novel Lamin A variant protein and nucleic acids encoding this variant, methods of using these molecules in detecting biological conditions associated with a LMNA mutation in a subject (e.g., HGPS, arteriosclerosis, and other age-related diseases), methods of treating such conditions, methods of selecting treatments, methods of screening for compounds that influence Lamin A activity, and methods of influencing the expression of LMNA or LMNA variants are also described. Oligonucleotides and other compounds for use in examples of the described methods are also provided, as are protein-specific binding agents, such as antibodies, that bind specifically to at least one epitope of a Lamin A variant protein preferentially compared to wildtype Lamin A, and methods of using such antibodies in diagnosis, treatment, and screening. Also provided are kits for carrying out the methods described herein.

Provided herein multispecific (e.g., bispecific) binding molecules comprising a first binding domain that binds an extracellular portion of dystroglycan and a second binding domain that binds laminin-2. Further provided herein are methods for making such binding molecules and uses of such binding molecules for treating and / or preventing alpha-dystroglycanopathies.

The present disclosure related to isolated laminin-521, methods for making recombinant laminin-521, host cells that express recombinant laminin-521, and compositions containing laminin-521. Laminin-521 can maintain stem cells in vitro pluripotency, enable self-renewal, and enable single cell survival of human embryonic stem cells. When pluripotent human embryonic stem cells are cultured on plates coated with recombinant laminin-521 (laminin-11), in the absence of differentiation inhibitors or feeder cells, the embryonic stem cells proliferate and maintain their pluripotency. It has also been discovered that human recombinant laminin-521 (laminin-11) provides single cell survival of stem cells after complete dissociation into a single cell suspension. Useful cell culture mediums containing at most 3.9 ng / ml of beta fibroblast growth factor (bFGF) are also described herein.

The invention provides a nutrient medium composition and associated methods for lengthening the useful life of a culture of muscle cells. Disclosed is a method of culturing mammalian muscle cells, including preparing one or more carriers coated with a covalently bonded monolayer of trimethoxy-silylpropyl-diethylenetriamine (DETA); verifying DETA monolayer formation by one or more associated optical parameters; suspending isolated fetal rat skeletal muscle cells in serum-free medium according to medium composition 1; plating the suspended cells onto the prepared carriers at a predetermined density; leaving the carriers undisturbed for cells to adhere to the DETA monolayer; covering the carriers with a mixture of medium 1 and medium 2; and incubating. A cell nutrient medium composition includes Neurobasal, an antibiotic-antimycotic composition, cholesterol, human TNF-alpha, PDGF BB, vasoactive intestinal peptides, insulin-like growth factor 1, NAP, r-Apolipoprotein E2, purified mouse Laminin, beta amyloid, human tenascin-C protein, rr-Sonic hedgehog Shh N-terminal, and rr-Agrin C terminal.

The invention relates to a highly bioactive extracellular matrix material and a preparation method and an application thereof. The material is prepared from raw materials with combined use of ultra-high pressure and cavity internal and external perfusion. The preparation method mainly includes the steps: raw material obtaining and preparation, and pretreatment; extracellular matrix mechanical separation; ultra-high pressure crushing and decellularizing; cell content elution and antigen elimination; and ultimately disinfection, sterilization and preservation. Compared with an extracellular matrix obtained by decellularizing through a mechanical oscillation method and a chemical reagent or biological reagent method, the extracellular matrix obtained by the preparation method has the retention amount of adhesion proteins, growth factors, proteoglycans, glycoproteins, glycosaminoglycans and other bioactive components significantly improved; at the same time, the mechanical strength is wellretained, the decellularizing is thorough, and viruses and other biological supporters are removed cleanly and industrialized production is convenient.

The present invention relates to the immunotherapB of cancer, in particular several tumor entities including hematological malignancies. The present invention relates to tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. In particular, the present invention relates to two novel peptide sequences derived from HLA class I or II molecules of human oncofoetal antigen immature laminin receptor (OFA / iLR), which can be used in vaccine compositions for eliciting anti-tumor immune responses.

Unregulated angiogenesis is associated with a variety of pathological conditions. Tumor growth and metastasis is dependent on the development of new blood vessels. The development of new blood vessels in the eye, or ocular neovascularization, has been implicated in a variety of serious ocular diseases. For instance, choroidal neovascularization is linked to age-related macular degeneration, while retinal neovascularization is linked to diabetic retinopathy. The present invention is based on the discovery of a peptide sequence, C16Y, which inhibits ocular neovascularization and tumor growth in vivo. C16Y is a scrambled version of the C16 peptide sequence from the y1 chain of laminin-1. Unlike C16, which is an angiogenic stimulator, C16Y has been shown to inhibit angiogenesis. The present invention discloses methods of treating ocular neovascularization and cancer using both full-length and truncated versions of the C16Y.

Provided herein multispecific (e.g., bispecific) binding molecules comprising a first binding domain that binds an extracellular portion of dystroglycan and a second binding domain that binds laminin-2. Further provided herein are methods for making such binding molecules and uses of such binding molecules for treating and / or preventing alpha-dystroglycanopathies.

The invention discloses a biological protective covering and a preparation method thereof. The biological protective covering is made of a substrate namely animal intestinal membranes, which have been crosslinked and fixed by a non-aldehyde fixing agent and subjected to an antigen removal treatment. An active modification layer, which contains fibronectin, laminin, or vitronectin that can adhere to cells, or an antibacterial sustained-release layer containing antibacterial drugs is arranged on the surface of the substrate. The biological protective covering is made of thin and tough animal intestinal membranes, and is light, soft, and user-friendly. The intestinal membranes are semi-permeable, gas and steam can penetrate the intestinal membranes, but bacteria cannot go through the intestinal membranes. Moreover, the intestinal membranes have been subjected to a multi-aspect antigen removal treatment to effectively remove the immunogenicity, the surface is subjected to active modification, the surface can aggregate epithelial cells and fibroblast to promote wound healing; the antibacterial drugs can be sustained-released, the anti-infection effect is enhanced, and the using performance and protective effect are better than those of dressing or protective covering made of pig skin.

Disclosed is the novel myokine known as myonectin (CTRP15), an isolated nucleic acid encoding the myonectin (CTRP15) gene, and the amino acid sequence encoding the myonectin (CTRP15) protein. Methods of isolation of the nucleic acid, protein, polypeptides and methods of making antibodies to the myonectin (CTRP15) protein are provided. The use of myonectin (CTRP15) in the modulation of lipid and / or glucose metabolism, suppressing the expression of autophagy genes, inhibiting LC3 lipidation and autophagosome-dependent p62 degradation, and activating the Akt / mTOR pathway is also provided.

The invention belongs to the technical field of medicine, and relates to a hexamethoxyflavanone-rhamnosyl-rhamnoside and application thereof. The hexamethoxyflavanone-rhamnosyl-rhamnoside is prepared by the following steps: carrying out solvent extraction and extraction separation on murraya jasminorage, carrying out silica gel column separation, carrying out further separation by semipreparative chromatography, concentrating, and carrying out freeze-drying to obtain the finished hexamethoxyflavanone-rhamnosyl-rhamnoside product. The antitumor activity evaluation detects that the hexamethoxyflavanone-rhamnosyl-rhamnoside has low cytotoxicity; the hexamethoxyflavanone-rhamnosyl-rhamnoside has obvious inhibiting effects on the adhesion of colon cancer cells HT-29 and Fn (fibronectin) and the adhesion of HUVECs (human umbilical vein endothelial cells); the hexamethoxyflavanone-rhamnosyl-rhamnoside has obvious inhibiting effects on migration capacity (scratch heating experiment) and invasion capacity of HT-29; and the hexamethoxyflavanone-rhamnosyl-rhamnoside has obvious inhibiting effects on mouse in-vivo B16-F10 lung transfer. Therefore, the hexamethoxyflavanone-rhamnosyl-rhamnoside has tumor transfer inhibition activity, can be used for preparing anticancer drugs, and has favorable development and application prospects.

The invention discloses a beautifying method for resisting skin aging by a small needle autologous repair technology, which is characterized by comprising the following steps of: cleaning, disinfecting, injecting, massaging, repeatedly injecting normal saline with different magnitudes at different subcutaneous levels, and performing repairing. When in use, only the compound liquid containing rich nutritional ingredients needs to be injected into the subcutaneous part at the key point of aging prolapse, a minimal trauma is formed under the subcutaneous part by utilizing the soft stripping action of the liquid, and the autologous repair capability of human tissues is stimulated by the trauma. Meanwhile, various nutritional ingredients of the compound liquid provide nutrition for surrounding adipocytes, so that the adipocytes are recovered to be full and moist, newborn adherin and full fat achieve interaction, subcutaneous occupation is jointly increased, and the skin is recovered to be tight and flat.

Provided herein multispecific (e.g., bispecific) binding molecules comprising a first binding domain that binds an extracellular portion of dystroglycan and a second binding domain that binds laminin-2. Further provided herein are methods for making such binding molecules and uses of such binding molecules for treating and / or preventing alpha-dystroglycanopathies.

The invention discloses a cellulosome with improved catalytic activity and an assembly method and application thereof, and belongs to the technical field of biology. According to the assembly method,xylanase AExynM-Doc1 containing a docking domain and glucanase EG1-Doc2 containing a docking domain are expressed heterologously by using escherichia coli; fibronectin Coh1-Coh2 are surface-displayedby using saccharomyces cerevisiae, to obtain a recombinant yeast EBY100 / Coh1-Coh2; and the recombinant proteins AExynM-Doc1 and EG1-Doc2 are mixed with the recombinant yeast EBY100 / Coh1-Coh2, and arerespectively bound with the Coh1 and the Coh2 to finish in-vitro assembly of the cellulosome. According to the invention, the xylanase and glucanase with high catalytic activity are combined in scaffold protein of the cellosome, so that the synergistic catalytic action between the two enzymes is greatly improved, and lignocellulose can be more effectively degraded.

It is intended to provide a novel method of screening a drug with the use of a 67 kDa laminin receptor and a drug obtained thereby. A method of screening a drug having an effect of inhibiting cell proliferation, an angiogenesis inhibitory effect, an effect of inhibiting cancer cell metastasis, a nerve protecting effect, an antiallergic effect, an antiareteriosclerotic effect and / or an effect of inhibiting infection with Creutzfeldt-Jakob disease which involves the step of qualitatively or quantitatively measuring the degree of the binding of a test compound to a 67 kDa laminin receptor, and judging that the test compound is a drug having an effect of inhibiting cell proliferation, an angiogenesis inhibitory effect, an effect of inhibiting cancer cell metastasis, a nerve protecting effect, an antiallergic effect, an antiareteriosclerotic effect and / or an effect of inhibiting infection with Creutzfeldt-Jakob disease in the case where it is found out by the results of the measurement that the test compound binds to the 67 kDa laminin receptor, and a drug obtained thereby.

The invention provides a ligand antrum mucosal protein-18(AMP-18) of a laminin receptor (LR), which has an amino acid sequence as shown in SEQ ID No.1 in a sequence table. The ligand antrum mucosal protein-18(AMP-18) can bind with LR on the surface of gastric epithelial cells to inhibit the growth of stomach cancer cells and can be used to prepare drugs for treating tumor.

The invention provides a gel composition, biological scaffold gel as well as a preparation method and application of the biological scaffold gel. The gel composition is prepared from polyethylene glycol (PEG), collagen, laminin, RGD polypeptide, B27, N2, N-acetylcystine, Nicotinamide, a Wnt signaling pathway agonist, an epidermal growth factor and a ROCK inhibitor. The biological scaffold gel comprises the following components according to final concentration: 0.01-0.5 g / ml of PEG (Polyethylene Glycol); the content of collagen is 0.02 to 0.5 g / ml; the concentration of the laminin is 0.05 to 100 ng / ml; b27, 0.5 to 5 *; n2, 0.5 to 5 *; the concentration of the N-acetylcystine is 0.1 to 50 [mu] M; the concentration of the Nicotinamide is 10 to 200 [mu] M; the concentration of the Wnt signal channel agonist is 25 to 500 ng / ml; eGF (Epidermal Growth Factor) with the concentration of The concentration of the ROCK inhibitor is 0.5 ng / ml to 100 ng / ml; the concentration of the RGD polypeptide is 0.1 mg / ml to 1 mg / ml; all the components are dissolved in a buffer solution or a basic culture medium. According to the method, 3D culture of cells and tissues can be efficiently carried out, and formed 3D cultures such as cell clusters and organoids can simulate in-vivo three-dimensional tissue structures and gene expression characteristics.